Capricor Q2 2021 Earnings Report
Key Takeaways
Capricor Therapeutics reported revenue of $200,000 and a net loss of $4.7 million, or $0.21 per share, for the three months ended June 30, 2021. The company's cash and cash equivalents balance totaled approximately $38.1 million as of June 30, 2021.
Completed an end-of-phase-II meeting with FDA and planning to move forward with start-up activities for a Phase III pivotal trial for CAP-1002 for the treatment of DMD.
Completed GLP toxicology study and are nearing completion of IND-enabling studies for multivalent exosome-mRNA vaccine candidate.
Signed exclusive, worldwide licensing agreement with Johns Hopkins University to include engineered exosomes for vaccines and therapeutics as part of the Company’s exosome technology portfolio.
Enrollment of INSPIRE clinical trial for treating severe COVID-19 patients increase with the emerging prevalence of the Delta variant.
Capricor
Capricor
Forward Guidance
Based on our current pipeline and operating plan, the Company’s cash position is expected to be sufficient to support operations for at least two years.